BrightHeart has achieved a significant milestone by securing the CE mark for its B-Right AI Platform, facilitating its European launch. This advancement will be showcased at the upcoming Fetal Medicine Foundation (FMF) World Congress in Vienna in June 2026.
The B-Right AI Platform aims to enhance the accuracy of prenatal ultrasounds, which are often challenging due to the complexities involved in evaluating numerous fetal structures within a limited timeframe. Current detection rates for congenital anomalies can vary widely, with some studies indicating that up to 50% of such conditions go undetected. This inconsistency is largely attributed to differences in operator skill and resource availability.
BrightHeart's solution includes real-time guidance for sonographers, which minimizes variability in procedures and promotes adherence to established protocols. Additionally, the platform provides advanced analysis of critical fetal organs, delivering results that reflect the diagnostic expertise of seasoned clinicians, irrespective of the operator's experience level.
Backed by peer-reviewed studies demonstrating high sensitivity and specificity in detecting severe defects, BrightHeart's platform is positioned to significantly improve prenatal screening quality. CEO Cécile Dupont emphasized the importance of this technology in making high-quality prenatal assessments accessible across various healthcare settings. The FMF World Congress will serve as a pivotal platform for BrightHeart to engage with the international fetal medicine community and advocate for standardized ultrasound practices that enhance congenital anomaly detection.